NEW YORK (GenomeWeb) – John Hopkins University spinout Personal Genome Diagnostics plans to develop cancer diagnostic products that it will bring through US Food and Drug Administration clearance.

At last week's Molecular Medicine Tri-Conference in San Francisco, PGDx Founder and CSO Victor Velculescu told GenomeWeb that the company is in the midst of "moving from being a service company to a product company," and aims to bring both tissue-based targeted sequencing tests as well as NGS-based liquid biopsy tests through FDA clearance in the next couple of years.